Collaboration to support preclinical drug discovery research 


Fusion Antibodies has entered into a commercial collaboration with Eurofins to provide laboratories worldwide with high-quality, cost-effective and efficient services that work with one another to support biotherapeutic discovery.  

Under the agreement, Fusion Antibodies will provide comprehensive pre-clinical antibody development services from discovery, engineering, and critical reagent supply to Eurofins so that together they can provide a complete workflow solution for researchers. This includes Fusion Antibodies services for antibody generation, characterisation, sequencing, engineering and expression, and Eurofins Discovery’s in vivo and in vitro services, such as efficacy models, bioanalytical services, biomarker development, phenotypic assays and safety assessment.  

Dr Richard Jones, CEO of Fusion Antibodies, said: “Eurofins is an established global provider of testing and laboratory services, and this partnership is a natural fit with Fusion’s mission to enable pharmaceutical and diagnostic companies to develop innovative products in the most efficient and cost-effective way.” 

Dr Julie Gormley, Business Development Director of Fusion Antibodies, said: “This partnership brings together two world leaders in their respective fields and will enable scientists to focus on their research while our services ensure efficient and robust results. I look forward to working closely with colleagues at Eurofins Discovery throughout 2021 and beyond.” 

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free